PHARMACEUTICAL PREPARATION TREATING MITOCHONDRIAL

Brand Owner (click to sort) Address Description
EXER-MITOKINE Mark Tarnopolsky 19 Oakwood Place Hamilton, ON L8S4C9 Canada Pharmaceutical preparation for treating mitochondrial disorders, and diseases or conditions relating to mitochondrial dysfunction or deficiencies including obesity, diabetes, metabolic syndrome, and hypoglycemia; pharmaceutical namely oral, inhalational, parenteral, topical pharmaceuticals containing proteins, protein kinase or phosphatas; nutraceuticals, vitamins, minerals, nutritional and dietary supplements for the treatment of mitochondria disorders, deficiencies or conditions arising from mitochondrial dysfunction or deficiencies;
MITOKINE Mark Tarnopolsky 19 Oakwood Place Hamilton, ON L8S4C9 Canada Pharmaceutical preparation for treating mitochondrial disorders, and diseases or conditions relating to mitochondrial dysfunction or deficiencies including obesity, diabetes, metabolic syndrome, and hypoglycemia; pharmaceutical namely oral, inhalational, parenteral, topical pharmaceuticals containing proteins, protein kinase or phosphatas; nutraceuticals, vitamins, minerals, nutritional and dietary supplements for the treatment of mitochondria disorders, deficiencies or conditions arising from mitochondrial dysfunction or deficiencies;Medical and scientific research in the field of mitochondrial disorders, and diseases or conditions relating to mitochondrial dysfunction or deficiencies including obesity, diabetes, metabolic syndrome, and hypoglycemia; Medical research; Pharmaceutical research and development;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. This invention provides methods for treating cellular blood components and other cells containing mitochondria to improve vital qualities of the cells by contacting the cells with a mitochondrial enhancer to the cells. Mitochondrial enhancers prevent damage to and rejuvenate mitochondria and cells containing mitochondria. Mitochondrial enhancers include alloxazines and related compounds, such as riboflavin. Cells are optionally treated with photoradiation to reduce pathogens with may be present, before, after, and/or during treatment with mitochondrial enhancer. Treating with mitochondrial enhancer enables utilization of higher photoradiation energies, which achieves better pathogen reduction. When platelets are treated with mitochondrial enhancer, treated platelets may be stored for longer times than untreated platelets before they are administered to patients.